Jeffrey Stark, MD, vice president, head of medical immunology, UCB, discusses ongoing clinical trials and the development of real-world data to understand the effectiveness of bimekizumab-bkzx in a broader context.
Jeffrey Stark, MD
Advertisement
Jeff Stark, MD, is vice president and head of medical immunology, UCB. He is also a rheumatologist by training and leads UCB’s medical affairs team across the key focus areas of dermatology and rheumatology.
Articles by Jeffrey Stark, MD
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, analyzes the Bimzelx Navigate program, a comprehensive support system developed to empower patients prescribed bimekizumab-bkzx (Bimzelx; UCB).
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals and the remaining challenges.
Advertisement
Latest Updated Articles
Bimekizumab-bkzx Expands Treatment Options for Inflammatory ConditionsFebruary 10th 2025
Advertisement
Advertisement
Trending on AJMC
1
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
2
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5